Abstract
The introduction of biologics has rapidly expanded treatment options for patients suffering from severe plaque psoriasis. Currently, the mainstay of biologic therapy for psoriasis centers around three key classes: Anti‐tumor necrosis factor (TNF), Anti‐Interleukin (IL)‐23, and Anti‐IL‐17, such as Secukinumab and Ixekizumab. Though generally considered to have favorable safety profiles, there have been growing reports of dermatologic adverse events in the setting of biologic therapy initiation.

This publication has 2 references indexed in Scilit: